Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOPIC: Treatment of Hospitalised Inpatients for Hepatitis C
NCT03981211Phase 4Terminated
- Sponsor
- The Kirby Institute
- Start
- Feb 2021
- Primary completion
- Dec 2024
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label trial of glecaprevir, pibrentasvir and sofosbuvir in hepatitis C (HCV) (2 cohorts), sponsored by The Kirby Institute. Primary endpoint: Sustained Virologic Response at 12 Weeks. Started Feb 2021; status: terminated.
02
Drugs
glecaprevirpibrentasvirsofosbuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03981211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03981211.